Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Phase 2

Withdrawn

• Conditions: Non-Small-Cell Lung Cancer
• Interventions: Drug: Dabrafenib; Drug: Trametinib

• Registration Number: NCT02672358
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This is an open-label, multicenter, non-randomized, single arm, phase II study to assess efficacy and safety of the dabrafenib and trametinib combination in Japanese patients with any line, stage IV NSCLC harboring a confirmed BRAF V600E mutation.

Patients will receive oral dabrafenib twice daily and oral trametinib once daily combination therapy. Patients may continue study treatment until disease progression, unacceptable adverse events, start of a new anti-cancer therapy, consent withdrawal, death, or end of the study. Patients who have met the criteria for disease progression (PD) according to RECIST v1.1 may continue to receive study treatment if the investigator believes the patient is receiving clinical benefit and the patient is willing to continue on study treatment. After discontinuation of study treatment, all patients will be followed for survival until death, lost to follow-up, withdrawal of consent, or end of study.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-02-01
• Study First Submitted QC: 2016-02-01
• Study First Posted: 2016-02-03
• Status Verified: 2018-08
• Last Update Submitted: 2018-08-08
• Last Update Posted: 2018-08-10
• Study Start: 2018-09-03
• Primary Completion: 2019-09-02
• Study Completion: 2020-12-07

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Histologically- or cytologically-confirmed diagnosis of NSCLC stage IV (according to AJCC Staging 7th Edition)
• Presence of a BRAF V600E mutation in lung cancer tissue. BRAF V600E mutation tested by local laboratory (e.g. study center laboratory, local laboratory company) with proper quality control and license to operation by local health authority is allowed.
• Measurable disease according to RECIST v1.1.

Read More

Exclusion Criteria

• Previous treatment with a BRAF inhibitor (including but not limited to dabrafenib, vemurafenib, encorafenib, and XL281/BMS-908662) or MEK inhibitor (including but not limited to trametinib, cobimetinib, binimetinib, AZD6244, and RDEA119) prior to start of study treatment

• Patients with brain metastases are excluded if their brain metastases are:

  • Symptomatic OR
  • Treated (surgery, radiation therapy) but not clinically and radiographically stable 3 weeks after local therapy (as assessed by contrast enhanced magnetic resonance imaging [MRI] or computed tomography [CT]), OR
  • Asymptomatic and untreated but >1 cm in the longest dimension

• History of malignancy with confirmed activating RAS mutation at any time.

• History of interstitial lung disease or pneumonitis

• A history or current evidence of retinal vein occlusion (RVO)

• Current evidence of unstable aneurysm or one that needs treatment

Other protocol-defined inclusion/exclusion may apply.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Dabrafenib +Trametinib	Dabrafenib	Oral Dabrafenib plus Oral Trametinib
Dabrafenib +Trametinib	Trametinib	Oral Dabrafenib plus Oral Trametinib

Primary Outcome Measures

Name	Time	Method
Overall Response Rate (ORR) by investigator assessment	Approximately 2 years	ORR, defined as the percentage of patients with a confirmed CR or PR by investigator assessment as per RECIST v1.1 criteria

Secondary Outcome Measures

Name	Time	Method
Disease control rate (DCR)	Approximately 2 years	DCR, defined as the proportion of patients with best overall response of CR, PR, or SD.
Overall survival (OS)	Approximately 2 years	OS, defined as the time from the date of first dose until death due to any cause.
Duration of response (DOR)	Approximately 2 years	DOR, defined for the subset of patients with confirmed CR or PR, as the time from first documented evidence of CR or PR until time of first documented disease progression or death due to any cause.
Progression-free survival (PFS)	Approximately 2 years	PFS, defined as the interval between first dose and the earliest date of disease progression or death due to any cause.